Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

This publication has 25 references indexed in Scilit:

• Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
  Published by Oxford University Press (OUP) ,2003
• Management of acute myocardial infarction in patients presenting with ST-segment elevation
  European Heart Journal, 2003
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
  European Heart Journal, 2002
• ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction—2002: Summary Article
  Circulation, 2002
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  BMJ, 2002
• Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
  New England Journal of Medicine, 2001
• Antithrombotic Agents in Coronary Artery Disease
  Chest, 2001
• A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: A double-blind, randomized, dose-finding study
  European Heart Journal, 1997
• Low-molecular-weight heparin during instability in coronary artery disease
  The Lancet, 1996
• Reactivation of Unstable Angina after the Discontinuation of Heparin
  New England Journal of Medicine, 1992